Aktie A3D1PX BLUE WATER VENTURES INTERNATIONAL, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Blue Water Ventures International, Inc.

Aktien

A3D1PX

US09609E1055

BWVI

Verzögert OTC Markets
Andere Börsenplätze
 21:58:09 16.05.2024 		% 5 Tage % 1. Jan.
0,035 USD +194,12 % Intraday Chart für Blue Water Ventures International, Inc. +159,26 % -43,55 %
2023 Psycheceutical Bioscience, Inc. kündigt Wechsel im Vorstand an CI
2023 Psycheceutical Bioscience, Inc. ernennt Neilank K. Jha zum neuen Executive Chairman CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Psycheceutical Bioscience, Inc. Announces Chief Executive Officer Changes
Psycheceutical Bioscience, Inc. Appoints Neilank K. Jha as Its New Executive Chairman
Blue Water Ventures International, Inc. announced that it expects to receive $5 million in funding
Psycheceutical Bioscience, Inc Announces First Patient Has Been Dosed in Its Phase I Study to Evaluate Its Patented Neurodirectâ„¢ Ketamine Topical Delivery System for the Treatment of Post Traumatic Stress Disorder
Veru Sells ENTADFI Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones
Psycheceutical Bioscience, Inc. Named a 2023 Top 10 Biotech Startup by Life Sciences Review
Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD
Psycheceutical Bioscience, Inc. Announces Publication of Pre-Clinical Observational Data Supports Potential of its NeuroDirect™ Ketamine Topical Cream as Treatment for PTSD
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer
Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer
Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3D1PX Aktie
  4. Nachrichten Blue Water Ventures International, Inc.
  5. Andere Sprachen